ECM
LGND icon

ETrade Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

ETrade Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$1.24M Sell
20,764
-7,364
-26% -$502K 0.02% 321
2020
Q2 		$1.96M Sell
28,128
-982
-3% -$62.3K 0.04% 220
2020
Q1 		$1.32M Buy
29,110
+6,436
+28% +$365K 0.03% 239
2019
Q4 		$1.48M Sell
22,674
-4,341
-16% -$290K 0.03% 263
2019
Q3 		$1.68M Buy
27,015
+1,992
+8% +$125K 0.04% 235
2019
Q2 		$1.78M Buy
25,023
+960
+4% +$70.7K 0.05% 229
2019
Q1 		$1.89M Buy
24,063
+9,282
+63% +$703K 0.05% 212
2018
Q4 		$1.25M Buy
14,781
+1,717
+13% +$183K 0.04% 240
2018
Q3 		$2.24M Sell
13,064
-2,841
-18% -$428K 0.06% 179
2018
Q2 		$2.06M Buy
15,905
+3,078
+24% +$343K 0.06% 177
2018
Q1 		$1.32M Sell
12,827
-2,132
-14% -$211K 0.04% 255
2017
Q4 		$1.28M Buy
14,959
+250
+2% +$21.7K 0.04% 293
2017
Q3 		$1.25M Buy
14,709
+3,047
+26% +$241K 0.04% 267
2017
Q2 		$883K Sell
11,662
-644
-5% -$45K 0.03% 308
2017
Q1 		$813K Sell
12,306
-896
-7% -$58.9K 0.03% 322
2016
Q4 		$837K Sell
13,202
-484
-4% -$30.5K 0.04% 286
2016
Q3 		$871K Sell
13,686
-937
-6% -$68.8K 0.04% 260
2016
Q2 		$1.09M Sell
14,623
-1,178
-7% -$87.4K 0.06% 194
2016
Q1 		$1.06M Sell
15,801
-56
-0.4% -$3.4K 0.06% 189
2015
Q4 		$1.07M Buy
15,857
+308
+2% +$19K 0.06% 176
2015
Q3 		$831K Buy
15,549
+1,188
+8% +$72.1K 0.05% 199
2015
Q2 		$904K Sell
14,361
-1,031
-7% -$56.3K 0.05% 196
2015
Q1 		$740K Buy
15,392
+1,379
+10% +$52.8K 0.04% 218
2014
Q4 		$465K Buy
14,013
+2,423
+21% +$78.8K 0.03% 316
2014
Q3 		$340K Buy
11,590
+6,315
+120% +$210K 0.02% 345
2014
Q2 		$205K Buy
5,275
+2,989
+131% +$121K 0.01% 413
2014
Q1 		$96K Buy
+2,286
New +$95.3K 0.01% 492

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

ETrade Capital Management's LGND Position: Q3 2020 in Review

ETrade Capital Management reduced its Ligand Pharmaceuticals (LGND) stake by 26% in Q3 2020, selling an estimated $502K and leaving 20,764 shares worth $1.24M. The position accounts for 0.02% of the portfolio, ranked #321.

ETrade Capital Management first reported a position in LGND in Q1 2014 and has held it in 27 quarters since. The position peaked at $2.24M in Q3 2018. 252 funds tracked by Wall St. Rank hold LGND as of Q3 2020.

  • ETrade Capital Management held 20,764 shares of Ligand Pharmaceuticals worth $1.24M as of Q3 2020.
  • ETrade Capital Management sold 7,364 Ligand Pharmaceuticals shares in Q3 2020, an estimated $502K.
  • Ligand Pharmaceuticals made up 0.02% of ETrade Capital Management's portfolio in Q3 2020, its #321 holding.
  • ETrade Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2014 and has held it in 27 quarters since.
  • ETrade Capital Management's Ligand Pharmaceuticals position peaked at $2.24M in Q3 2018.
  • 252 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.